JB Pharma profit rises 13% to Rs 111 crore in Q2FY23

Revenues rose 36% YoY to Rs 809 crore in Q2FY23, compared to Rs 593 crore in Q2FY22.Earnings before interest, depreciation and taxes (EBITDA) increased by 44% to Rs 202 crores. The EBITDA margins expanded 140 basis points YoY to 25% in Q2FY23.